Page last updated: 2024-11-04

hexamethonium bromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5938
SCHEMBL ID143264
MeSH IDM0028071

Synonyms (76)

Synonym
hexamethonium bromide [inn:ban:jan]
bromure d'hexamethonium [inn-french]
1,6-hexanediaminium, n,n,n,n',n',n'-hexamethyl-, dibromide
einecs 200-249-7
bromuro de hexametonio [inn-spanish]
nsc 163965
esametonio bromuro [dcit]
hexamethonii bromidum [inn-latin]
ammonium, hexamethylenebis(trimethyl-, dibromide
hexamethonium (dibromure d')
hexamethylenebis(trimethylammonium bromide)
AKOS015832953
EU-0100622
55-97-0
hexamethonium bromide
hexamethionium bromide
vegolysin
vegolysen
hexonium dibromide
bistrium bromide
esametina
hexamethylenebis(trimethylammonium) bromide
nsc-163965
simpatoblock
hexameton
hexamethonium dibromide
gangliostat
D02204
hexamethonium bromide (jan/inn)
hexamethonium bromide (tn)
NCGC00093993-03
NCGC00093993-02
SPECTRUM1503297
NCGC00093993-01
H 0879
hexamethone bromide
HMS502B05
hexane-1,6-bis(trimethylammonium bromide)
H0481
HMS1922A08
HMS3261N06
unii-8j77x3s603
1,6-hexanediaminium, n1,n1,n1,n6,n6,n6-hexamethyl-, bromide (1:2)
hexamethonii bromidum
8j77x3s603 ,
bromure d'hexamethonium
esametonio bromuro
bromuro de hexametonio
S4069
CCG-39330
FT-0603235
LP00622
n,n,n,n',n',n'-hexamethylhexamethylenediammonium dibromide
hexamethonium bromide [mi]
hexamethonium bromide [jan]
hexamethonium bromide [inn]
hexamethonium bromide [mart.]
hexamethonium bromide [who-dd]
HY-B0569
hexamethonium (bromide) ,
SCHEMBL143264
FAPSXSAPXXJTOU-UHFFFAOYSA-L
hexamethylene-bis(trimethylammonium)bromide
NCGC00261307-01
tox21_500622
mfcd00011787
SR-01000075320-2
SR-01000075320-9
n1,n1,n1,n6,n6,n6-hexamethylhexane-1,6-diaminium bromide
BCP24467
Q27270624
D90883
DTXSID50883229
trimethyl[6-(trimethylazaniumyl)hexyl]azanium dibromide
AS-57514
trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dibromide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.04740.100020.879379.4328AID588453
TDP1 proteinHomo sapiens (human)Potency0.05800.000811.382244.6684AID686979
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency11.22020.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Acetylcholine receptor subunit alphaTetronarce californica (Pacific electric ray)Kd1.80001.80001.80001.8000AID225705
Acetylcholine receptor subunit betaTetronarce californica (Pacific electric ray)Kd1.80001.80001.80001.8000AID225705
Acetylcholine receptor subunit gammaTetronarce californica (Pacific electric ray)Kd1.80001.80001.80001.8000AID225705
Acetylcholine receptor subunit deltaTetronarce californica (Pacific electric ray)Kd1.80001.80001.80001.8000AID225705
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID478866Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 by micro dilution assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The bisnaphthalimides as new active lead compounds against Plasmodium falciparum.
AID225705Compound was evaluated for the binding constant for association with nicotinic acetylcholine receptor (nAChR)1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
Bis-catechol-substituted redox-reactive analogues of hexamethonium and decamethonium: stimulated affinity-dependent reactivity through iron peroxide catalysis.
AID151197In vitro activity against Plasmodium falciparum2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts.
AID478865Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as parasite-specific LDH release after 72 hrs by Malstat assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The bisnaphthalimides as new active lead compounds against Plasmodium falciparum.
AID158688Inhibitory activity against Plasmodium falciparum1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID478868Cytotoxicity against mouse J774.1 cells after 48 hrs by alamar blue satining2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The bisnaphthalimides as new active lead compounds against Plasmodium falciparum.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's2 (18.18)29.6817
2010's6 (54.55)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.78 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]